Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract OT1-1-02: PI3K-Akt-mTOR pathway analysis to obtain further insight in the efficacy of everolimus in combination with exemestane in metastatic, ER-positive breast cancer: A Dutch breast cancer research group (BOOG) study

Dinja T Kruger, Karin Beelen, Connie R Jimenez, Maurice PHM Jansen, Stefan Sleijfer, Sabine C Linn, Epie Boven

Cancer Res (2015) 75 (9_Supplement): OT1-1-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-OT1-1-02

Published: 01 May 2015

View article

Journal Articles

Abstract P6-08-09: Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients

Cancer Res (2015) 75 (9_Supplement): P6-08-09.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-P6-08-09

Published: 01 May 2015

View article

Journal Articles

Abstract P3-06-09: Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

Cancer Res (2015) 75 (9_Supplement): P3-06-09.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-06-09

Published: 01 May 2015

View article

Journal Articles

Abstract 5109: Proteomics of murine BRCA1 deficient breast tumors identifies DNA repair proteins with prognostic value in human breast cancer

Marc O. Warmoes, Janneke Jaspers, Maarten P.G. Massink, Thang Pham, Sander R. Piersma, Sven Rottenberg, Epie Boven, Hanne Meijers-Heijboer, Quinten Waisfisz, Jos Jonkers, Connie R. Jimenez

Cancer Res (2011) 71 (8_Supplement): 5109.

DOI: https://doi.org/10.1158/1538-7445.AM2011-5109

Published: 15 April 2011

View article

Journal Articles

Abstract 4563: Quantitative proteomics of genetic mouse models for human breast cancer: Identification of BRCA1-associated proteins involved in DNA-repair

Marc O. Warmoes, Janneke Jaspers, Maarten P.G. Massink, Thang V. Pham, Sander R. Piersma, Epie Boven, Hanne Meijer-Heijboer, Quinten Waisfisz, Jos Jonkers, Connie R. Jimenez

Cancer Res (2010) 70 (8_Supplement): 4563.

DOI: https://doi.org/10.1158/1538-7445.AM10-4563

Published: 15 April 2010

View article

Journal Articles

Abstract 4956: CD34^bright/CD133^neg candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab

Laura Vroling, Astrid A.M. van der Veldt, Richard R de Haas, Gerrit Jan Schuurhuis, Hester van Cruijsen, Alfons J.M. van den Eertwegh, Klaas Hoekman, Victor W.M. van Hinsbergh, Epie Boven, Egbert F. Smit, Henk J. Broxterman

Cancer Res (2008) 68 (9_Supplement): 4956.

DOI: https://doi.org/10.1158/1538-7445.AM2008-4956

Published: 15 May 2008

View article

Journal Articles

CD34^bright/CD133^neg candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab

Laura Vroling, Astrid van der Veldt, Richard de Haas, Gerrit Jan Schuurhuis, Hester van Cruijsen, Alfons van den Eertwegh, Klaas Hoekman, Victor van Hinsbergh, Epie Boven, Egbert Smit, Henk Broxterman

Cancer Res (2008) 68 (9_Supplement): 4956.

Published: 01 May 2008

View article

Journal Articles

Analysis of circulating endothelial (progenitor) cells by flow cytometry and a short-term colony assay (CFU-EC)

Laura Vroling, Yuana Yuana, Klaas Hoekman, Hester Van Cruijsen, Epie Boven, Chad Gundy, Gerrit Jan Schuurhuis, Henk J. Broxterman

Cancer Res (2006) 66 (8_Supplement): 71–72.

Published: 15 April 2006

View article

Journal Articles

Synergistic cytotoxicity of a conditionally replicating adenovirus expressing p53 and oxaliplatin on human colon cancer cell lines

Dinja Oosterhoff, Victor W. Van Beusechem, Epie Boven, Herbert M. Pinedo, Winald R. Gerritsen

Cancer Res (2004) 64 (7_Supplement): 268.

Published: 01 April 2004

View article

Journal Articles

Induction of drug resistance by basic Fibroblast Growth Factor (bFGF) in human melanoma cells

Dennis Fontijn, Frits J. Peters, Monique C. Duyndam, Herbert M. Pinedo, Epie Boven

Cancer Res (2004) 64 (7_Supplement): 140–141.

Published: 01 April 2004

View article

Journal Articles

Inhibition of angiogenesis by subtoxic concentrations of microtubule-interfering anticancer agents

Marcel N. Bijman, Geerten P. Van Nieuw Amerongen, Klaas Hoekman, Epie Boven

Cancer Res (2004) 64 (7_Supplement): 944.

Published: 01 April 2004

View article

Journal Articles

Novel releasable linker technologies for targeted drug delivery: Activity of plasmin-activated prodrugs in tumor xenografts

Franciscus M. De Groot, Epie Boven, Laetitia Devy, Agnes Noel, Jean-Michel Foidart, Patrick Beusker, Hans W. Scheeren

Cancer Res (2004) 64 (7_Supplement): 1060.

Published: 01 April 2004

View article

Journal Articles

Development and Molecular Characterization of a 2′,2′-Difluorodeoxycytidine-resistant Variant of the Human Ovarian Carcinoma Cell Line A2780

Veronique W. T. Ruiz van Haperen, Gijsbert Veerman, Staffan Eriksson, Epie Boven, Alexander P. A. Stegmann, Mario Hermsen, Jan B. Vermorken, Herbert M. Pinedo, Godefridus J. Peters

Cancer Res (1994) 54 (15): 4138–4143.

Published: 01 August 1994

View article

Journal Articles

Phase II Preclinical Drug Screening in Human Tumor Xenografts: A First European Multicenter Collaborative Study

Epie Boven, Benjamin Winograd, Dietmar P. Berger, M. Patrick Dumont, Boudewijn J. M. Braakhuis, Øystein Fodstad, Simon Langdon, Heiner H. Fiebig

Cancer Res (1992) 52 (21): 5940–5947.

Published: 01 November 1992

View article

Journal Articles

Time Dependence of the Selective Modulation of Cisplatin-induced Nephrotoxicity by WR2721 in the Mouse

Marco Treskes, Epie Boven, Ulbe Holwerda, Herbert M. Pinedo, Wim J. F. van der Vijgh

Cancer Res (1992) 52 (8): 2257–2260.

Published: 01 April 1992

View article

Journal Articles

Specific Killing of Human Melanoma Cells by ¹²⁵I-Labeled 9.2.27 Monoclonal Antibody

Tore Lindmo, Epie Boven, James B. Mitchell, George Morstyn, Paul A. Bunn, Jr.

Cancer Res (1985) 45 (10): 5080–5087.

Published: 01 October 1985

View article

Journal Articles

Comparative Activity and Distribution Studies of Five Platinum Analogues in Nude Mice Bearing Human Ovarian Carcinoma Xenografts

Epie Boven, Wim J. F. van der Vijgh, Maria M. Nauta, Hennie M. M. Schlüper, Herbert M. Pinedo

Cancer Res (1985) 45 (1): 86–90.

Published: 01 January 1985

View article

NARROW

Abstract OT1-1-02: PI3K-Akt-mTOR pathway analysis to obtain further insight in the efficacy of everolimus in combination with exemestane in metastatic, ER-positive breast cancer: A Dutch breast cancer research group (BOOG) study

Abstract P6-08-09: Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients

Abstract P3-06-09: Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

Abstract 5109: Proteomics of murine BRCA1 deficient breast tumors identifies DNA repair proteins with prognostic value in human breast cancer

Abstract 4563: Quantitative proteomics of genetic mouse models for human breast cancer: Identification of BRCA1-associated proteins involved in DNA-repair

Abstract 4956: CD34^bright/CD133^neg candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab

CD34^bright/CD133^neg candidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab

Analysis of circulating endothelial (progenitor) cells by flow cytometry and a short-term colony assay (CFU-EC)

Synergistic cytotoxicity of a conditionally replicating adenovirus expressing p53 and oxaliplatin on human colon cancer cell lines

Induction of drug resistance by basic Fibroblast Growth Factor (bFGF) in human melanoma cells

Inhibition of angiogenesis by subtoxic concentrations of microtubule-interfering anticancer agents

Novel releasable linker technologies for targeted drug delivery: Activity of plasmin-activated prodrugs in tumor xenografts

Development and Molecular Characterization of a 2′,2′-Difluorodeoxycytidine-resistant Variant of the Human Ovarian Carcinoma Cell Line A2780

Phase II Preclinical Drug Screening in Human Tumor Xenografts: A First European Multicenter Collaborative Study

Time Dependence of the Selective Modulation of Cisplatin-induced Nephrotoxicity by WR2721 in the Mouse

Specific Killing of Human Melanoma Cells by ¹²⁵I-Labeled 9.2.27 Monoclonal Antibody

Comparative Activity and Distribution Studies of Five Platinum Analogues in Nude Mice Bearing Human Ovarian Carcinoma Xenografts

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only